miRagen Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- miRagen Therapeutics's estimated annual revenue is currently $3.9M per year.
- miRagen Therapeutics received $38.5M in venture funding in February 2018.
- miRagen Therapeutics's estimated revenue per employee is $31,870
- miRagen Therapeutics's total funding is $271.7M.
- miRagen Therapeutics's current valuation is $65M. (Jul 2019)
Employee Data
- miRagen Therapeutics has 123 Employees.
- miRagen Therapeutics grew their employee count by 54% last year.
miRagen Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CFO | Reveal Email/Phone |
2 | PRESIDENT AND CHIEF EXECUTIVE OFFICER | Reveal Email/Phone |
3 | Facilities Manager | Reveal Email/Phone |
4 | Research Scientist | Reveal Email/Phone |
5 | Associate Scientist III | Reveal Email/Phone |
6 | PT Accounting/Payroll | Reveal Email/Phone |
miRagen Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | 0% | N/A | N/A |
#2 | $2.8M | 18 | 13% | N/A | N/A |
#3 | $70.2M | 453 | -1% | N/A | N/A |
#4 | $1.6M | 10 | -66% | N/A | N/A |
#5 | $3.7M | 24 | -8% | N/A | N/A |
#6 | $2.9M | 37 | 28% | N/A | N/A |
#7 | $3.1M | 20 | 25% | N/A | N/A |
#8 | $2.5M | 16 | -20% | N/A | N/A |
#9 | $9.1M | 59 | 0% | N/A | N/A |
#10 | $4.2M | 27 | -7% | N/A | N/A |
What Is miRagen Therapeutics?
miRagen Therapeutics, Inc., (NASDAQ: MGEN), is a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. At miRagen, we recognize the importance of creating strategic relationships within the biotech and pharmaceutical industries and with academic institutions globally. This collaborative approach is making important contributions in our efforts to create miRNA-targeting therapies. miRagen's areas of focus include hematological malignancies, pathological fibrosis, neuro-degeneration, and cardiovascular disease. In 2011, the company formed a strategic partnership with Servier, a privately-run, French research-based pharmaceutical company, to advance miRNA-targeting drug candidates for the treatment of cardiovascular disease.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$271.7M
Total Funding
123
Number of Employees
$3.9M
Revenue (est)
54%
Employee Growth %
$65M
Valuation
N/A
Accelerator
miRagen Therapeutics News
Understand the influence of the Rna-Based Therapeutics And Vaccines Market with detailed analysis is provided for each segment, including an...
This table compares Sera Prognostics and Viridian Therapeutics' revenue, ... The company was formerly known as Miragen Therapeutics,...
... Dicerna Pharmaceuticals, Mirna Therapeutics, Quark Pharmaceuticals, RXi Pharmaceuticals, Silence Therapeutics, Benitec Biopharma, miRagen Therapeutics,...
Other Companies in Boulder
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $22.5M | 125 | -7% | N/A |
#2 | $15M | 125 | 8% | N/A |
#3 | $25.6M | 125 | -6% | N/A |
#4 | $31.3M | 125 | 14% | N/A |
#5 | $18.3M | 126 | -44% | N/A |
miRagen Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2009-06-03 | $4.0M | A | Article | |
| 2012-04-25 | $20.0M | B | Remeditex Ventures LLC | Article |
| 2014-06-30 | $7.0M | Second | Multile | Article |
| 2015-11-12 | $41.0M | C | MRL Ventures | Article |
| 2016-11-04 | $40.0M | Undisclosed | Multiple | Article |
| 2018-02-06 | $Undisclosed | Undisclosed | Jefferies LLC, | Article |
| 2018-02-12 | $38.5M | Undisclosed | Jefferies LLC, | Article |